{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:19:14Z","timestamp":1787584754281,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82202271"],"award-info":[{"award-number":["82202271"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Guangzhou Basic and Applied Basic Research Foundation","award":["2025A04J5522"],"award-info":[{"award-number":["2025A04J5522"]}]},{"DOI":"10.13039\/501100013050","name":"Guangdong Provincial Applied Science and Technology Research and Development Program","doi-asserted-by":"publisher","award":["A2022436"],"award-info":[{"award-number":["A2022436"]}],"id":[{"id":"10.13039\/501100013050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00535-026-02406-4","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T12:23:53Z","timestamp":1775823833000},"page":"977-989","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lenvatinib plus hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin versus lenvatinib alone for advanced hepatocellular carcinoma: a multicenter retrospective cohort study"],"prefix":"10.1007","volume":"61","author":[{"given":"Feng","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qicong","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"11","key":"2406_CR1","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41571-023-00816-4","volume":"20","author":"TF Greten","year":"2023","unstructured":"Greten TF, Villanueva A, Korangy F, Ruf B, Yarchoan M, Ma L, et al. Biomarkers for immunotherapy of hepatocellular carcinoma. Nat Rev Clin Oncol. 2023;20(11):780\u201398.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2406_CR2","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2406_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol"},{"issue":"12","key":"2406_CR4","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41575-024-00967-4","volume":"21","author":"L-Y Mak","year":"2024","unstructured":"Mak L-Y, Liu K, Chirapongsathorn S, Yew KC, Tamaki N, Rajaram RB, et al. Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions. Nat Rev Gastroenterol Hepatol. 2024;21(12):834\u201351.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"2406_CR5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","volume":"150","author":"J Bruix","year":"2016","unstructured":"Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835\u201353.","journal-title":"Gastroenterology"},{"issue":"10126","key":"2406_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet"},{"issue":"8","key":"2406_CR7","doi-asserted-by":"publisher","first-page":"2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus Durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):2100070.","journal-title":"NEJM Evid"},{"issue":"20","key":"2406_CR8","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"3","key":"2406_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","volume":"10","author":"S Cappuyns","year":"2024","unstructured":"Cappuyns S, Corbett V, Yarchoan M, Finn RS, Llovet JM. Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: a review. JAMA Oncol. 2024;10(3):395.","journal-title":"JAMA Oncol"},{"issue":"1","key":"2406_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jhep.2018.02.008","volume":"69","author":"N Lyu","year":"2018","unstructured":"Lyu N, Kong Y, Mu L, Lin Y, Li J, Liu Y, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2018;69(1):60\u20139.","journal-title":"J Hepatol"},{"key":"2406_CR11","doi-asserted-by":"publisher","first-page":"175883592312250","DOI":"10.1177\/17588359231225040","volume":"16","author":"K Zheng","year":"2024","unstructured":"Zheng K, Wang X. Techniques and status of hepatic arterial infusion chemotherapy for primary hepatobiliary cancers. Ther Adv Med Oncol. 2024;16:17588359231225040.","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"2406_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000514174","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 2021;10(3):181\u2013223.","journal-title":"Liver Cancer"},{"issue":"1","key":"2406_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12072-023-10599-6","volume":"18","author":"M Zhao","year":"2024","unstructured":"Zhao M, Guo Z, Zou Y-H, Li X, Yan Z-P, Chen M-S, et al. Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations. Hepatol Int. 2024;18(1):4\u201331.","journal-title":"Hepatol Int"},{"issue":"28","key":"2406_CR14","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1200\/JCO.2012.44.5643","volume":"31","author":"S Qin","year":"2013","unstructured":"Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil\/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31(28):3501\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2406_CR15","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1200\/JCO.21.01963","volume":"40","author":"N Lyu","year":"2022","unstructured":"Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, Phase III trial (FOHAIC-1). J Clin Oncol. 2022;40(5):468\u201380.","journal-title":"J Clin Oncol"},{"key":"2406_CR16","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1200\/JCO.22.01142","volume":"41","author":"SH Li","year":"2023","unstructured":"Li SH, Mei J, Cheng Y, Li Q, Wang QX, Fang CK, et al. Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: a multicenter, Phase III, randomized study. J Clin Oncol. 2023;41:1898\u2013908.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2406_CR17","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","volume":"5","author":"M He","year":"2019","unstructured":"He M, Li Q, Zou R, Shen J, Fang W, Tan G, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5(7):953.","journal-title":"JAMA Oncol"},{"issue":"5706","key":"2406_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58\u201362.","journal-title":"Science"},{"issue":"1","key":"2406_CR19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358\u201380.","journal-title":"Hepatology"},{"issue":"12","key":"2406_CR20","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(12):1399\u2013410.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2406_CR21","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1007\/s12072-022-10398-5","volume":"16","author":"K Patwala","year":"2022","unstructured":"Patwala K, Prince DS, Celermajer Y, Alam W, Paul E, Strasser SI, et al. Lenvatinib for the treatment of hepatocellular carcinoma\u2014a real-world multicenter Australian cohort study. Hepatol Int. 2022;16(5):1170\u20138.","journal-title":"Hepatol Int"},{"key":"2406_CR22","doi-asserted-by":"publisher","first-page":"175883592110027","DOI":"10.1177\/17588359211002720","volume":"13","author":"M He","year":"2021","unstructured":"He M, Liang R, Zhao Y, Xu Y, Chen H, Zhou Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2021;13:17588359211002720.","journal-title":"Ther Adv Med Oncol"},{"key":"2406_CR23","doi-asserted-by":"publisher","first-page":"175883592211166","DOI":"10.1177\/17588359221116608","volume":"14","author":"J Huynh","year":"2022","unstructured":"Huynh J, Cho MT, Kim EJ-H, Ren M, Ramji Z, Vogel A. Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function. Ther Adv Med Oncol. 2022;14:175883592211166.","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"2406_CR24","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1159\/000523849","volume":"11","author":"D Xia","year":"2022","unstructured":"Xia D, Bai W, Wang E, Li J, Chen X, Wang Z, et al. Lenvatinib with or without concurrent drug-eluting beads transarterial chemoembolization in patients with unresectable, advanced hepatocellular carcinoma: a real-world, multicenter, retrospective study. Liver Cancer. 2022;11(4):368\u201382.","journal-title":"Liver Cancer"},{"issue":"37","key":"2406_CR25","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1080\/14796694.2024.2397328","volume":"20","author":"W Kang","year":"2024","unstructured":"Kang W, Kim YJ, Kim SU, Seo YS, Kim J-W, Kim JH, et al. Real-world safety and effectiveness of lenvatinib in unresectable hepatocellular carcinoma in Korea: post-marketing study. Future Oncol. 2024;20(37):2949\u201359.","journal-title":"Future Oncol"},{"issue":"2","key":"2406_CR26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1148\/radiol.2018171541","volume":"287","author":"Z Peng","year":"2018","unstructured":"Peng Z, Chen S, Wei M, Lin M, Jiang C, Mei J, et al. Advanced recurrent hepatocellular carcinoma: treatment with sorafenib alone or in combination with transarterial chemoembolization and radiofrequency ablation. Radiology. 2018;287(2):705\u201314.","journal-title":"Radiology"},{"key":"2406_CR27","doi-asserted-by":"publisher","first-page":"1212577","DOI":"10.3389\/fimmu.2023.1212577","volume":"14","author":"J Yang","year":"2023","unstructured":"Yang J, Guo Z, Song M, Pan Q, Zhao J, Huang Y, et al. Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFR\u03b2 complex in hepatocellular carcinoma. Front Immunol. 2023;14:1212577.","journal-title":"Front Immunol"},{"issue":"9","key":"2406_CR28","doi-asserted-by":"publisher","first-page":"102298","DOI":"10.1016\/j.xcrm.2025.102298","volume":"6","author":"R Xing","year":"2025","unstructured":"Xing R, Mei J, Zuo Z, Zou H, Yu X, Xu J, et al. Enhanced formation of tertiary lymphoid structures shapes the anti-tumor microenvironment in hepatocellular carcinoma after FOLFOX-HAIC therapy. Cell Rep Med. 2025;6(9):102298.","journal-title":"Cell Rep Med"},{"key":"2406_CR29","doi-asserted-by":"publisher","first-page":"103940","DOI":"10.1016\/j.critrevonc.2023.103940","volume":"184","author":"Z-N Ding","year":"2023","unstructured":"Ding Z-N, Meng G-X, Xue J-S, Liu H, Yang L-S, Li R-Z, et al. Systemic therapy with or without locoregional therapy for advanced hepatocellular carcinoma: a systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2023;184:103940.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"2406_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.5152\/tjg.2024.23071","volume":"35","author":"Z Zong","year":"2024","unstructured":"Zong Z, Tang R, Li M, Xiong X, Li D, Fan J, et al. Efficiency and stability of transarterial chemoembolization combined with or without lenvatinib for unresectable hepatocellular carcinoma. Turk J Gastroenterol. 2024;35(3):212\u201322.","journal-title":"Turk J Gastroenterol"},{"issue":"1","key":"2406_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1200\/JCO.22.00392","volume":"41","author":"Z Peng","year":"2023","unstructured":"Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2023;41(1):117\u201327.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2406_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000531377","volume":"13","author":"M Kudo","year":"2024","unstructured":"Kudo M, Ueshima K, Saeki I, Ishikawa T, Inaba Y, Morimoto N, et al. A phase 2, prospective, multicenter, single-arm trial of transarterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable intermediate-stage hepatocellular carcinoma: TACTICS-L trial. Liver Cancer. 2024;13(1):99\u2013112.","journal-title":"Liver Cancer"},{"issue":"2","key":"2406_CR33","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3892\/ol.2024.14480","volume":"28","author":"Y Li","year":"2024","unstructured":"Li Y, Liu X, Liu J, Yang L, Wei S, Li J, et al. Lenvatinib in combination with transarterial chemoembolization vs. sorafenib in combination with transarterial chemoembolization for unresectable hepatocellular carcinoma: a network meta\u2011analysis. Oncol Lett. 2024;28(2):347.","journal-title":"Oncol Lett"},{"key":"2406_CR34","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.2147\/JHC.S418387","volume":"10","author":"X Chang","year":"2023","unstructured":"Chang X, Wu H, Ning S, Li X, Xie Y, Shao W, et al. Hepatic arterial infusion chemotherapy combined with lenvatinib plus humanized programmed death receptor-1 in patients with high-risk advanced hepatocellular carcinoma: a real-world study. J Hepatocell Carcinoma. 2023;10:1497\u2013509.","journal-title":"J Hepatocell Carcinoma"},{"key":"2406_CR35","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.2147\/JHC.S432134","volume":"10","author":"Y Xiao","year":"2023","unstructured":"Xiao Y, Zhu G, Xie J, Luo L, Deng W, et al. Pretreatment neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with unresectable hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy combined with lenvatinib and camrelizumab. J Hepatocell Carcinoma. 2023;10:2049\u201358.","journal-title":"J Hepatocell Carcinoma"},{"key":"2406_CR36","doi-asserted-by":"publisher","first-page":"919069","DOI":"10.3389\/fmed.2022.919069","volume":"9","author":"Y Xu","year":"2022","unstructured":"Xu Y, Fu S, Mao Y, Huang S, Li D, Wu J. Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma. Front Med. 2022;9:919069.","journal-title":"Front Med"},{"key":"2406_CR37","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.2147\/JHC.S472286","volume":"11","author":"J Jiang","year":"2024","unstructured":"Jiang J, Zhang H, Lai J, Zhang S, Ou Y, Fu Y, et al. Efficacy and safety of transarterial chemoembolization plus lenvatinib with or without tislelizumab as the first-line treatment for unresectable hepatocellular carcinoma: a propensity score matching analysis. J Hepatocell Carcinoma. 2024;11:1607\u201322.","journal-title":"J Hepatocell Carcinoma"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02406-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02406-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02406-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:44:32Z","timestamp":1781948672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-026-02406-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2406"],"URL":"https:\/\/doi.org\/10.1007\/s00535-026-02406-4","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the institutional review board of Guangdong Provincial People\u2019s Hospital (Approval No. KY-Q-2021-066-03).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all participants to participate in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}